创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology bioidentical models: what are the main features

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-07-11 16:06
  • Views:

(Summary description)With the rapid development of the biomedical field, the demand for experimental models is increasing. Although traditional animal models simulate human physiological processes to a certain extent, the differences in species and incomplete simulation of the immune system lead to large discrepancies between experimental results and clinical data. For this reason, with its profound scientific background and strong technical strength, InnoModels Biotechnology (Beijing) Co., Ltd. has successfully developed a series of homologous models, which provide a more accurate and reliable modeling basis for research in the field of biomedicine. In this article, we will introduce the characteristics of homology models of InnoModels Biotechnology in detail.

InnoModels Biotechnology bioidentical models: what are the main features

(Summary description)With the rapid development of the biomedical field, the demand for experimental models is increasing. Although traditional animal models simulate human physiological processes to a certain extent, the differences in species and incomplete simulation of the immune system lead to large discrepancies between experimental results and clinical data. For this reason, with its profound scientific background and strong technical strength, InnoModels Biotechnology (Beijing) Co., Ltd. has successfully developed a series of homologous models, which provide a more accurate and reliable modeling basis for research in the field of biomedicine. In this article, we will introduce the characteristics of homology models of InnoModels Biotechnology in detail.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-07-11 16:06
  • Views:
Information

With the rapid development of the biomedical field, the demand for experimental models is increasing. Although traditional animal models simulate human physiological processes to a certain extent, the differences in species and incomplete simulation of the immune system lead to large discrepancies between experimental results and clinical data. For this reason, with its profound scientific background and strong technical strength, InnoModels Biotechnology (Beijing) Co., Ltd. has successfully developed a series of homologous models, which provide a more accurate and reliable modeling basis for research in the field of biomedicine. In this article, we will introduce the characteristics of homology models of InnoModels Biotechnology in detail.
1. Accuracy of Genetic Engineering Homology Models
Based on bioinformatics and genomics technology, the Genetic Engineering Homology Model of InnoModels Biotechnology is able to construct a gene sequence model that is homologous to the target organisms by comparing and analyzing the sequences of biological genomes. This feature enables the model to more accurately reflect the real genomic information of the organisms, which provides a powerful support for the research of gene function, drug development, disease prevention and treatment and other fields. Compared with the traditional animal model, the genetic engineering homology model is more accurate at the gene level, making the experimental results more reliable.
2、Stability and multi-cell reconstruction of immune system humanized model
The humanized model of the immune system of InnoModels Biotechnology has remarkable stability and multi-cell reconstruction ability. The model successfully realizes the stable reconstruction of the immune system, improves the modeling success rate of the experiment, and reduces the coefficient of variation within the group, which makes the experimental results more reliable and stable. At the same time, the model was able to reconstruct a variety of immune cells including T cells, B cells, NK cells, macrophages, DC cells, etc., thus simulating the complexity of the human immune system more realistically. The number of immune cells reconstructed reaches or approaches the concentration of human immune cells, providing a more realistic environment for drug testing.

 


3、Personalized and close to the clinic of human tumor xenograft platform (PDX)
The PBMC-PDX dual humanized model of InnoModels Biotechnology is another important achievement of the company. The model uses tumor and PBMC from the same patient for modeling, which makes the experimental results closer to the clinical reality. This feature makes the model more valuable in the development of tumor immunology drugs. At the same time, the model also successfully solves the main problems of tumor growth and PBMC antagonism and cycle matching in the immune system tumor model, which significantly improves the success rate of experiments and overcomes the problem of short drug delivery window due to graft-versus-host disease.
4. Rich model library and high-throughput screening platform
InnoModels' model library has collected more than 50 types of murine tumor cell lines with different primary locations, which can provide high-throughput in vivo/in vitro drug efficacy screening and evaluation for new drug research and development enterprises. This feature enables new drug R&D companies to quickly screen new immunotherapy alternatives, simplifying the decision-making process and improving R&D efficiency.
5、Wide range of applications
Homology models from InnoModels Biotechnology are widely used in drug discovery, disease prevention and treatment, genetics research and other fields. In the field of drug research and development, genetic engineering homology model can be used for screening and validation of drug targets, providing more accurate guidance for the development of new drugs; in the field of disease prevention and treatment, the model can be used to study the pathogenesis of diseases and the mechanism of drug action, and provide new ideas and methods for the prevention and treatment of diseases; in the field of genetics research, the model can be used in the diagnosis and treatment of genetic diseases and other areas. research.
In conclusion, by virtue of its accuracy, stability, multi-cell reconstruction capability, personalized and close clinical features, as well as rich model library and high-throughput screening platform, the homology model of InnoModels Biotechnology has demonstrated great potential and value in the research in the field of biomedicine. With the continuous development and improvement of the technology, it is believed that the homology model of InnoModels will play an even more important role in the future research in the field of biomedicine.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司